S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"How war impacts the stock market" (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"How war impacts the stock market" (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"How war impacts the stock market" (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"How war impacts the stock market" (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
NYSE:BVS

Bioventus (BVS) Stock Forecast, Price & News

$2.96
0.00 (0.00%)
(As of 06/2/2023 08:48 PM ET)
Compare
Today's Range
$2.88
$3.02
50-Day Range
$0.93
$2.96
52-Week Range
$0.80
$9.90
Volume
519,500 shs
Average Volume
1.14 million shs
Market Capitalization
$231.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Bioventus MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
85.8% Upside
$5.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$2.99 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.15) to $0.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

697th out of 980 stocks

Surgical & Medical Instruments Industry

70th out of 97 stocks


BVS stock logo

About Bioventus (NYSE:BVS) Stock

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Receive BVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

BVS Stock News Headlines

Bioventus Inc. (NYSE:BVS) CEO Buys $291,250.00 in Stock
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Recap: Bioventus Q1 Earnings
Bioventus Reports First Quarter Financial Results
7BVS : Earnings Preview: Bioventus
Bioventus (BVS) Set to Announce Earnings on Thursday
Bioventus Announces CEO Leadership Change
Bioventus (NYSE:BVS) PT Lowered to $5.00
Here’s Why Bioventus (BVS) Declined in Q4
See More Headlines

BVS Price History

BVS Company Calendar

Last Earnings
3/31/2023
Today
6/04/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,120
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+85.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-158,700,000.00
Pretax Margin
-67.04%

Debt

Sales & Book Value

Annual Sales
$512.12 million
Cash Flow
$1.65 per share
Book Value
$3.07 per share

Miscellaneous

Free Float
71,933,000
Market Cap
$231.68 million
Optionable
Not Optionable
Beta
0.23

Key Executives

  • Mr. Kenneth M. Reali (Age 56)
    CEO & Director
    Comp: $1.77M
  • Mr. Mark SingletonMr. Mark Singleton (Age 53)
    Sr. VP, CFO & Principal Accounting Officer
  • Mr. Anthony James
    VP of Operations and Quality
  • Ms. Alessandraa Pavesio (Age 55)
    Sr. VP & Chief Science Officer
  • Mr. David Crawford
    VP of Investor Relations & Treasurer
  • Mr. Anthony D'Adamio (Age 61)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Katrina J. Church (Age 60)
    Sr. VP & Chief Compliance Officer
  • Mr. Jeff Welch
    VP of Bus. Devel.
  • Mr. Christopher K. Yamamoto
    Sr. VP of Corp. Devel. & Strategy
  • Mr. Leigh Ann Stradford
    Sr. VP & Chief HR Officer













BVS Stock - Frequently Asked Questions

Should I buy or sell Bioventus stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BVS, but not buy additional shares or sell existing shares.
View BVS analyst ratings
or view top-rated stocks.

What is Bioventus' stock price forecast for 2023?

5 Wall Street research analysts have issued 1-year target prices for Bioventus' stock. Their BVS share price forecasts range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 85.8% from the stock's current price.
View analysts price targets for BVS
or view top-rated stocks among Wall Street analysts.

How have BVS shares performed in 2023?

Bioventus' stock was trading at $2.61 on January 1st, 2023. Since then, BVS shares have increased by 13.4% and is now trading at $2.96.
View the best growth stocks for 2023 here
.

When is Bioventus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BVS earnings forecast
.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) announced its quarterly earnings results on Friday, March, 31st. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.11. The firm had revenue of $125.83 million for the quarter, compared to analysts' expectations of $134.09 million. Bioventus had a positive trailing twelve-month return on equity of 0.49% and a negative net margin of 55.77%.

When did Bioventus IPO?

(BVS) raised $126 million in an initial public offering on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

What is Bioventus' stock symbol?

Bioventus trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVS."

Who are Bioventus' major shareholders?

Bioventus' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.49%), Geode Capital Management LLC (0.82%), State Street Corp (0.69%), Strs Ohio (0.42%), Stephens Inc. AR (0.40%) and Charles Schwab Investment Management Inc. (0.30%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins.
View institutional ownership trends
.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioventus' stock price today?

One share of BVS stock can currently be purchased for approximately $2.96.

How much money does Bioventus make?

Bioventus (NYSE:BVS) has a market capitalization of $231.68 million and generates $512.12 million in revenue each year. The company earns $-158,700,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis.

How many employees does Bioventus have?

The company employs 1,120 workers across the globe.

How can I contact Bioventus?

Bioventus' mailing address is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. The official website for the company is www.bioventus.com. The company can be reached via phone at 919-474-6700 or via email at investor.relations@bioventus.com.

This page (NYSE:BVS) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -